Results 111 to 120 of about 16,087 (221)

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8277-8287, September 2026.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier, Ramon A. Hofmann, Michael Roden, Wolfgang Rathmann, Oliver Kuss   +4 more
wiley   +1 more source

Dapagliflozin binds PRMT7 to inhibit p38 MAPK phosphorylation and macrophage foam cell formation in atherosclerosis. [PDF]

iScience
Fang Y, Li S, Qin C, Chou Y, Sun N, Ma Y, Zhou Y, Li H, Feng H, Yuan X, Ye H, Wu X, Kang N, Chen H, Gao L, Cao F.   +15 more
europepmc   +1 more source

A Four‐Week Treatment With Dapagliflozin Is Associated With a Reduction in Insulin‐Stimulated Renal Cortical Glucose Uptake: A Post Hoc Analysis From a Pilot Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8329-8336, September 2026.
ABSTRACT Introduction and Objective Treatment with sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) reduces the risk of both cardiovascular and renal outcomes in type 2 diabetes (T2D). The specific mechanism by which this happens has not yet been clarified.
Shawn Gugliandolo, Cassandra Morciano, Andrea Guarneri, Gian Pio Sorice, Marta Giaccari, Luigi Cappannoli, Umberto Capece, Amelia Splendore, Adriana Avolio, Lorenzo Diego Greco, Patricia Iozzo, Rossana Moroni, Alfredo Pontecorvi, Maria Lucia Calcagni, Francesco Burzotta, Domenico D'Amario, Filippo Crea, Lucia Leccisotti, Francesca Cinti   +18 more
wiley   +1 more source

Enhancing the Therapeutic Profile of Dapagliflozin: Chitosan Nanoparticle Encapsulation for Intestinal Applications. [PDF]

FASEB Bioadv
Klonari A, Athinodorou AM, Papanikolaou E, Skonta A, Bellou MG, Lakkas L, Tsamis KI, Markopoulos GS, Stamatis H, Bozidis P, Peschos D, Simos YV.   +11 more
europepmc   +1 more source

Association of Sodium‐Glucose Cotransporter‐2 Inhibitors With Incident Gout Risk: A Population‐Based Comparative Cohort Study With Genetic Evidence From Mendelian Randomisation

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8230-8241, September 2026.
ABSTRACT Aim Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are known to reduce serum urate levels, yet their specific impact on gout incidence in the Korean population remains underexplored. We investigated the association between SGLT2i use and incident gout using real‐world data and Mendelian randomisation (MR) analysis. Materials and Methods We
Hong Sang Choi, Jaejun Heo, Sungho Won, Sang Heon Suh, Chang Seong Kim, Eun Hui Bae, Juhee Ahn, Soo Wan Kim   +7 more
wiley   +1 more source

Correction: The effect of dapagliflozin on cardiorespiratory fitness in patients with coronary heart disease and type 2 diabetes mellitus following PCI: a single-center prospective randomized controlled study. [PDF]

BMC Cardiovasc Disord
Yang J, Li X, Tang L, Fan W, Li A, Zhou W, Pang J, Yuan Q, Zhong M, Hou J, Wang L, Liao W, Liu X, Cardiovascular B.   +13 more
europepmc   +1 more source

Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8347-8358, September 2026.
ABSTRACT Aims Orforglipron is a novel small‐molecule, once daily oral non‐peptide GLP‐1 receptor agonist. The hepatic safety profile in adults with obesity or overweight and/or type 2 diabetes (T2D) across seven orforglipron Phase 3 clinical trials was assessed.
Sean Wharton, Adam Stefanski, Jiaxun Chen, Girish Rao, Elvis Asare Twum, Max Denning   +5 more
wiley   +1 more source

Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Obese and Nonobese Healthy Adults Following Multiple Administration. [PDF]

Drug Des Devel Ther
Lee HW, Kim H, Park JS, Lee JH, Park JJ, Gwon MR, Cho JY, Seong SJ, Yoon YR.   +8 more
europepmc   +1 more source

Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS‐3 MRI

Liver International, Volume 46, Issue 9, September 2026.
ABSTRACT The patatin‐like phospholipase 3 (PNPLA3) I148M genetic variant is highly associated with steatotic liver disease. In the SURPASS‐3 MRI substudy, tirzepatide significantly reduced liver fat content (LFC) versus insulin degludec in insulin‐naïve patients with type 2 diabetes with metabolic dysfunction‐associated steatotic liver disease.
Kenneth Cusi, Amalia Gastaldelli, Laura Fernández Landó, Palash Sharma, Amelia Torcello‐Gómez, Ángel Rodríguez   +5 more
wiley   +1 more source

Sodium-Glucose Cotransporter 2 Inhibitors in Alport Syndrome: Emerging Clinical Evidence and Mechanistic Insights. [PDF]

Kidney360
Miyata KN, Miner JH.
europepmc   +1 more source